Adicet Bio, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Adicet Bio, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($116.80M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($117.12M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($142.66M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($69.79M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($62.00M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($36.68M) | Mar 15, 2022 |
| FY2019 | Dec 31, 2019 | ($28.89M) | Mar 12, 2020 |
| FY2019 | Sep 30, 2019 | ($24.45M) | Mar 12, 2020 |
| FY2019 | Jun 30, 2019 | ($18.33M) | Mar 12, 2020 |
| FY2019 | Mar 31, 2019 | ($11.07M) | Mar 12, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($122.11M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($127.62M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($152.04M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($72.55M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($61.43M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($39.19M) | Mar 15, 2022 |
| FY2019 | Dec 31, 2019 | ($29.44M) | Mar 12, 2020 |
| FY2019 | Sep 30, 2019 | ($25.16M) | Mar 12, 2020 |
| FY2019 | Jun 30, 2019 | ($19.17M) | Mar 12, 2020 |
| FY2019 | Mar 31, 2019 | ($11.69M) | Mar 12, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $99.13M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $99.32M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $106.04M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $71.25M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $48.94M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $34.33M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $23.69M | Mar 12, 2021 |
| FY2020 | Dec 31, 2018 | $14.72M | Mar 12, 2021 |
| FY2019 | Dec 31, 2017 | $16.84M | Mar 12, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($95.25M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($92.38M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($93.72M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($44.77M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($51.05M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($41.55M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | ($27.88M) | Mar 12, 2021 |
| FY2020 | Dec 31, 2018 | ($18.18M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2017 | ($10.99M) | Mar 12, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.74M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.12M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $4.46M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $16.78M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $13.05M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $990.0K | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $1.07M | Mar 12, 2021 |
| FY2020 | Dec 31, 2018 | $876.0K | Mar 12, 2021 |
| FY2019 | Dec 31, 2017 | $44.0K | Mar 12, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $192.36M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $220.22M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $207.30M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $330.69M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $338.94M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $153.84M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $81.59M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $109.94M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $55.19M | Mar 18, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.15M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $33.61M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $37.12M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $38.35M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $35.81M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $44.01M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $27.87M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $5.74M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $5.50M | Mar 18, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $159.21M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $186.61M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $170.18M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $292.34M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $303.13M | Mar 19, 2024 |
| FY2022 | Dec 31, 2020 | $109.83M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | ($60.37M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2018 | ($33.52M) | Mar 12, 2021 |
| FY2020 | Dec 31, 2017 | ($26.95M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2016 | $0 | Mar 12, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Mar 19, 2024 |
| FY2023 | Dec 31, 2022 | $19.46M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $19.46M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $20.09M | Mar 15, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($614.70M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($497.89M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($380.77M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($238.11M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($168.32M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($106.33M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | ($69.65M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | ($71.39M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($33.78M) | Mar 18, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.92M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $56.50M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $159.71M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $257.66M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $277.54M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $84.33M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $10.61M | Mar 12, 2021 |
| FY2020 | Dec 31, 2018 | $9.48M | Mar 12, 2021 |
| FY2018 | Dec 31, 2017 | $53.35M | Mar 18, 2019 |
| FY2018 | Dec 31, 2016 | $0 | Mar 18, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (16) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (21) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 15, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (16) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (21) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 15, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9.59M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 5.16M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 43.27M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 42.95M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | 39.74M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | 19.68M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | 2.16M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | 28.06M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | 5.66M | Mar 18, 2019 |